Elderberry interaction with pazopanib in a patient with soft‑tissue sarcoma: A case report and literature review

Agarwal,Nikki; Mangla,Ankit

doi:10.3892/mco.2024.2734

Elderberry interaction with pazopanib in a patient with soft‑tissue sarcoma: A case report and literature review

Authors:
- Nikki Agarwal
- Ankit Mangla
View Affiliations

Affiliations: Department of Pediatric Hematology and Oncology, Cleveland Clinic Children's Hospitals, Cleveland, OH 44195, USA, Department of Hematology and Oncology, University Hospital Seidman Cancer Center, Cleveland, OH 44106, USA
Published online on: March 20, 2024 https://doi.org/10.3892/mco.2024.2734
Article Number: 36
Copyright: © Agarwal et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Elderberry flower extract is marketed as an herbal supplement with purported benefits in boosting the immune system. The use of elderberry increased during the coronavirus pandemic. However, the interaction of elderberry with cytotoxic medicines has remained elusive. Pazopanib is a multikinase inhibitor approved for patients diagnosed with soft‑tissue sarcoma. The present study reported on the case of a middle‑aged woman diagnosed with localized intermediate‑grade sarcoma of the left sartorius muscle who received neoadjuvant pazopanib with radiation therapy. The patient had no other medical comorbidities and only took over‑the‑counter (OTC) elderberry supplements for numerous years to ‘boost’ her immune system. She started pazopanib at 400 mg per os (PO) daily, which was increased to 800 mg PO daily after a week. By week three on pazopanib, the patient reported intense nausea and a number of loose stools, requiring anti‑nausea medication. By the fourth week on pazopanib, laboratory tests showed grade 3 liver injury, as demonstrated by a fivefold rise in liver enzymes along with severe nausea and loose stools. All medications, including elderberry supplement, were stopped. Within two weeks of stopping all medicines, the liver enzymes started normalizing within two weeks and were normal by the end of four weeks. Pazopanib treatment was resumed without the recurrence of side effect. Pazopanib is metabolized in the liver via the cytochrome P 450 (CYP)3A4 enzyme pathway. Hence, potent inhibitors of CYP3A4 are avoided for concurrent use with pazopanib. Small in vitro studies on elderberry extracts have shown weak inhibition of CYP3A4. However, considering the wide usage of elderberry and the availability of mixed supplements OTC, it is essential to pursue clinical studies in cancer patients to understand the interactions of elderberry extracts with cytotoxic medicines. In this report, the scientific evidence behind the use of elderberry was reviewed and a hypothesis of its interaction with pazopanib was proposed.

View Figures

View References

1	Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA and Krzyzanowska MK: Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 99:592–600. 2007.PubMed/NCBI View Article : Google Scholar
2	Kessel KA, Lettner S, Kessel C, Bier H, Biedermann T, Friess H, Herrschbach P, Gschwend JE, Meyer B, Peschel C, et al: Use of complementary and alternative medicine (CAM) as part of the oncological treatment: Survey about patients' attitude towards CAM in a university-based oncology center in Germany. PLoS One. 11(e0165801)2016.PubMed/NCBI View Article : Google Scholar
3	Buckner CA, Lafrenie RM, Dénommée JA, Caswell JM and Want DA: Complementary and alternative medicine use in patients before and after a cancer diagnosis. Curr Oncol. 25:e275–e281. 2018.PubMed/NCBI View Article : Google Scholar
4	Choudhury NR: Elderberry supplements market outlook (2023 to 2033). https://www.futuremarketinsights.com/reports/elderberry-supplements-market. Accessed November 19, 2023.
5	Adams KK, Baker WL and Sobieraj DM: Myth busters: Dietary supplements and COVID-19. Ann Pharmacother. 54:820–826. 2020.PubMed/NCBI View Article : Google Scholar
6	Schutz FA, Choueiri TK and Sternberg CN: Pazopanib: Clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol. 77:163–171. 2011.PubMed/NCBI View Article : Google Scholar
7	Lee ATJ, Jones RL and Huang PH: Pazopanib in advanced soft tissue sarcomas. Signal Transduct Target Ther. 4(16)2019.PubMed/NCBI View Article : Google Scholar
8	van Meekeren M, Bovee J, van Coevorden F, van Houdt W, Schrage Y, Koenen AM, Miah AB, Zaidi S, Hayes AJ, Thway K, et al: A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma. Acta Oncol. 60:1557–1564. 2021.PubMed/NCBI View Article : Google Scholar
9	Weiss AR, Chen YL, Scharschmidt TJ, Xue W, Gao Z, Black JO, Choy E, Davis JL, Fanburg-Smith JC, Kao SC, et al: Outcomes after preoperative chemoradiation with or without pazopanib in non-rhabdomyosarcoma soft tissue sarcoma: A report from Children's oncology group and NRG oncology. J Clin Oncol. 41:4842–4848. 2023.PubMed/NCBI View Article : Google Scholar
10	National Center for Complementary and Integrative Health: Elderberry. National Institutes of Health, 2020. https://www.nccih.nih.gov/health/elderberry. Accessed November 19, 2023.
11	Ulbricht C, Basch E, Cheung L, Goldberg H, Hammerness P, Isaac R, Khalsa KP, Romm A, Rychlik I, Varghese M, et al: An evidence-based systematic review of elderberry and elderflower (Sambucus nigra) by the natural standard research collaboration. J Diet Suppl. 11:80–120. 2014.PubMed/NCBI View Article : Google Scholar
12	Pembleton M: Can elderberry treat the flu? The New York Times. NYT Parenting, 2020. https://www.nytimes.com/2020/04/17/parenting/elderberry-benefits-dangers.html. Accessed September 23, 2023.
13	Zakay-Rones Z, Varsano N, Zlotnik M, Manor O, Regev L, Schlesinger M and Mumcuoglu M: Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (Sambucus nigra L.) during an outbreak of influenza B Panama. J Altern Complement Med. 1:361–369. 1995.PubMed/NCBI View Article : Google Scholar
14	Zakay-Rones Z, Thom E, Wollan T and Wadstein J: Randomized study of the efficacy and safety of oral elderberry extract in the treatment of influenza A and B virus infections. J Int Med Res. 32:132–140. 2004.PubMed/NCBI View Article : Google Scholar
15	Tiralongo E, Wee SS and Lea RA: Elderberry supplementation reduces cold duration and symptoms in air-travellers: A randomized, double-blind placebo-controlled clinical trial. Nutrients. 8(182)2016.PubMed/NCBI View Article : Google Scholar
16	Centers for Disease Control (CDC). Poisoning from elderberry juice-California. MMWR Morb Mortal Wkly Rep. 33:173–174. 1984.PubMed/NCBI
17	Zhou SF, Xue CC, Yu XQ, Li C and Wang G: Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 29:687–710. 2007.PubMed/NCBI View Article : Google Scholar
18	Schrøder-Aasen T, Molden G and Nilsen OG: In vitro inhibition of CYP3A4 by the multiherbal commercial product Sambucus force and its main constituents Echinacea purpurea and Sambucus nigra. Phytother Res. 26:1606–1613. 2012.PubMed/NCBI View Article : Google Scholar
19	Thorn CF, Sharma MR, Altman RB and Klein TE: PharmGKB summary: Pazopanib pathway, pharmacokinetics. Pharmacogenet Genomics. 27:307–312. 2017.PubMed/NCBI View Article : Google Scholar
20	Langhammer AJ and Nilsen OG: In vitro inhibition of human CYP1A2, CYP2D6, and CYP3A4 by six herbs commonly used in pregnancy. Phytother Res. 28:603–610. 2014.PubMed/NCBI View Article : Google Scholar
21	Mangla A and Yadav U: Leiomyosarcoma. StatPearls Publishing, Treasure Island, FL, 2023.
22	Mangla A: Should neoadjuvant treatment be adopted more widely for patients with extremity soft tissue sarcoma in low-income countries? JCO Glob Oncol. 9(e2300110)2023.PubMed/NCBI View Article : Google Scholar
23	Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM and Pandite L: Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 15:4220–4227. 2009.PubMed/NCBI View Article : Google Scholar
24	Kolesarova A, Baldovska S, Kohut L and Sirotkin AV: Black elder and its constituents: Molecular mechanisms of action associated with female reproduction. Pharmaceuticals (Basel). 15(239)2022.PubMed/NCBI View Article : Google Scholar
25	Thakkar S, Anklam E, Xu A, Ulberth F, Li J, Li B, Hugas M, Sarma N, Crerar S, Swift S, et al: Regulatory landscape of dietary supplements and herbal medicines from a global perspective. Regul Toxicol Pharmacol. 114(104647)2020.PubMed/NCBI View Article : Google Scholar